Clinical Trial Update: Glucagon-like Peptide 1 Agonist Exenatide for Improved Glucose Control and Cardiac Function in Patients With Aortocoronary Bypass [Phase 3]

View source ↗

Summary

Phase 3 trial update evaluating exenatide, a GLP-1 receptor agonist, for improved glucose control and cardiac function in patients with coronary artery disease …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Coronary Artery Disease
• Heart Failure

Drugs mentioned

• EXENATIDE (EXENATIDE)

Snippet

Sponsor: Charles University, Czech Republic | Conditions: Coronary Artery Disease, Decreased Left Ventricular Function | Phase 3 | Status: COMPLETED